Discounted Cash Flow
Travere Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $133.6m | $-47.9m | $-4.9m | -35.9% | $-1.29 |
| 2017 | $154.9m (16.0%) | $-59.7m (-24.7%) | $6.5m (233.8%) | -38.6% (-7.5%) | $-1.54 (-19.4%) |
| 2018 | $164.2m (6.0%) | $-102.7m (-71.9%) | $-25.7m (-494.2%) | -62.5% (-62.2%) | $-2.54 (-64.9%) |
| 2019 | $175.3m (6.8%) | $-146.4m (-42.6%) | $-58.4m (-127.4%) | -83.5% (-33.6%) | $-3.46 (-36.2%) |
| 2020 | $198.3m (13.1%) | $-169.4m (-15.7%) | $-49.5m (15.2%) | -85.4% (-2.3%) | $-3.56 (-2.9%) |
| 2021 | $227.5m (14.7%) | $-180.1m (-6.3%) | $-19.9m (59.8%) | -79.2% (7.3%) | $-3.01 (15.4%) |
| 2022 | $212.0m (-6.8%) | $-278.5m (-54.6%) | $-261.0m (-1212.2%) | -131.3% (-65.9%) | $-4.37 (-45.2%) |
| 2023 | $145.2m (-31.5%) | $-111.4m (60.0%) | $-326.0m (-24.9%) | -76.7% (41.6%) | $-1.50 (65.7%) |
| 2024 | $233.2m (60.5%) | $-321.5m (-188.6%) | $-331.2m (-1.6%) | -137.9% (-79.8%) | $-4.08 (-172.0%) |
| 2025 | $490.7m (110.5%) | $-25.5m (92.1%) | $-20.4m (93.8%) | -5.2% (96.2%) | $-0.29 (92.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.